Kornimate/medical-research-clean huggingface dataset:
lateral neck flexor endurance and hyperlaxity

Conditions: Physical Endurance; Hypermobility, Joint; Muscular Weakness

Summary: the lateral neck flexor endurance test has been proposed to assess for unilateral muscular deficits. it is not known if individuals with hyperlaxity have different muscular endurance than individuals without hyperlaxity.

thirty individuals with systemic hyperlaxity as determined with the beighton scale will be assessed for lateral neck flexor endurance and compared to age and gender matched controls. basic demographic information will be collected, and all individuals will report neck disability index (ndi) and numeric pain rating scales (nprs) for their neck, as well duration of any neck pain. all participants will then undergo testing of lateral neck flexor muscle endurance, repeated twice on each side. average hold times will be compared for individuals with hyperlaxity (5 or greater on beighton scale) and the healthy age and gender matched controls. analysis will also include covariates of ndi scores, pain scores, and chronicity of symptoms.

Eligibility criteria:
inclusion criteria: systemic hyperlaxity of 5 or greater on beighton index, healthy age/gender matched controls exclusion criteria: * neck pain that spreads into the arms; * whiplash injury within the last 6 weeks; * diagnosed neuropathy or other nervous system disorders; * a history of spinal surgery in their neck; * fibromyalgia; * insulin dependent diabetes; * involved in legal activity regarding neck pain

Keywords: neck musculature endurance tests and measures
assessing ear damage in young cancer patients treated with cisplatin

Conditions: Ototoxicity; Unspecified Childhood Solid Tumor, Protocol Specific

Summary: rationale: new ways to find out about hearing loss after treatment with chemotherapy may improve the ability to plan cancer treatment and may help patients live more comfortably. purpose: this clinical trial is assessing ear damage in young cancer patients treated with cisplatin.

objectives: * determine the optimal criteria for determination of ototoxicity in younger cancer patients treated with cisplatin. * determine the feasibility of including ultrahigh frequency and evoked otoacoustic emission testing as adjunctive measures of ototoxicity. * determine the feasibility and necessity of central review of audiometry data. outline: this is a multicenter, prospective, cohort study. patients undergo hearing tests (conventional, otoscopy, ultrahigh frequency, and otoacoustic emission testing) before the first course of planned cisplatin, before each subsequent course of cisplatin, and 4 weeks after the last dose of cisplatin. patients who are scheduled to receive hematopoietic progenitor stem cell transplantation undergo hearing tests before the transplantation and 4 weeks after transplantation. projected accrual: a total of 282 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * planning to undergo treatment with any cisplatin-containing therapeutic regimen for cancer * treatment does not need to be on a cog therapeutic study * planning to enroll on clinical trial accl0431 patient characteristics: * not specified prior concurrent therapy: * see disease characteristics * no prior cisplatin

Keywords: ototoxicity unspecified childhood solid tumor, protocol specific
aerosolized randomized iloprost study ii (air - ii) long-term safety, tolerability, and clinical effects of iloprost inhalation in patients with primary or secondary pulmonary hypertension

Conditions: Hypertension, Pulmonary

Summary: the purpose of this study is to determine whether the study drug is effective in the long-term treatment of primary or secondary pulmonary hypertension

the study has previously been posted by schering ag, germany. schering ag, germany has been renamed to bayer schering pharma ag, germany. bayer schering pharma ag, germany is the sponsor of the trial.

Eligibility criteria:
inclusion criteria: * male or female patients * secondary pulmonary hypertension * mean pulmonary artery pressure equal or above 40 mmhg or primary pulmonary hypertension with a pressure equal or above 30 mmhg while resting during appropriate conventional treatment * written informed consent after having been duly informed about all diagnostic and therapeutic measures involved in the study exclusion criteria: * clinical instability at baseline * pulmonary venous obstruction * global respiratory insufficiency * obstructive ventilation disorders, interstitial pulmonary disease * cerebrovascular events * myocardial infarction or major cardiac surgery within 3 months prior to baseline * bleeding disorders or bleeding risk * severe hepatic insufficiency or renal insufficiency * malignant diseases * hiv positive * pregnancy, female patients of child-bearing potential without adequate contraception and nursing mothers * congenital or acquired valvular defects and myocardial function disorders not related to pulmonary hypertension * prior pulmonary embolism * collagenosis * pulmonary arterial or valvular stenosis

Keywords: primary or secondary pulmonary hypertension iloprost inhaled long-term treatment
ondexxya for intravenous injection 200mg drug use result investigation (all case investigation)

Conditions: Life Threatening Bleeding; Factor Xa Inhibitor

Summary: this survey will be conducted to investigate the status of occurrence of the safety specifications set for "safety specification" in patients who received ondexxya intravenous injection 200 mg. in addition, this survey will be implemented to understand the followings by collecting safety and effectiveness information under actual use conditions.

this survey will be conducted to investigate the status of occurrence of the safety specifications set for "safety specification" in patients who received ondexxya intravenous injection 200 mg. in addition, this survey will be implemented to understand the followings by collecting safety and effectiveness information under actual use conditions. 1. detection of unknown adverse drug reactions 2. incidence of adverse drug reactions under actual use conditions of the drug 3. factors that may affect the safety or effectiveness "safety specification" thrombotic events, infusion reaction, re-bleeding

Eligibility criteria:
inclusion criteria: * all patients treated with this drug to neutralize the anticoagulant effect of a fxa inhibitor (apixaban, rivaroxaban, or edoxaban) at onset of a life-threatening bleeding episode or a unarrestable bleeding episode. exclusion criteria: * n/a
short course radiotherapy followed intensive chemotherapy with delayed surgery for rectal cancer with synchronous distant metastasis

Conditions: Rectal Cancer; Liver Metastasis; Lung Metastasis

Summary: radical treatment of primary rectal cancer with synchronous distant metastases includes surgical resection of primary and metastatic lesion. however, primary rectal cancer in case of metastasized disease are often locally advanced disease and need downsizing before surgery. it is reported that pelvic recurrence rates and distant metastasis rates outside liver are 30\~35% and 60%, respectively. therefore, combined treatment with radiotherapy and chemotherapy is used. however, the sequence of treatment modalities is not yet definitely established and preoperative chemoradiotherapy and surgical resection is accepted as an option of treatment. conventional long course chemoradiotherapy delays administration of full-dose chemotherapy, and metastatic lesion can be progressed during chemoradiotherapy. in present study, we evaluate the efficacy of short course radiotherapy (scrt) followed by full-dose chemotherapy with delayed surgical resection of the primary tumor and metastases.


Eligibility criteria:
inclusion criteria: * pathologically confirmed adenocarcinoma of rectum * lower margin of tumor within 12 cm from anal verge * clinically locally advanced (t3-4 or n1-2) disease * potentially resectable and synchronous distant metastases in liver and/or lung. the resectability of metastatic lesions is determined by size, number, location, general condition, liver function, and lung function. * over 18 years * eastern cooperative oncology group performance status 0-2 * proper organ function (hemoglobin ≥ 10 g/dl, absolute neutrophil count (anc) ≥ 1,500/mm3, platelet ≥ 100,000/mm3, creatinine ≤ 1.5 mg/dl, clearance of creatinine \>50 ml/min using cockcroft-gault formula, bilirubin ≤ 1.5 x upper limit of normal (uln), liver enzyme (aspartate aminotransferase/alanine transaminase/alkaline phosphatase) ≤ 2.5 x uln) * subject who should sign on the informed consent form before participate the trial. exclusion criteria: * metastases in other organ except liver or lung * history of other type of malignancies within 3 years other than non-melanoma of the skin or carcinoma in situ of cervix * hereditary colorectal cancer (fap, hnpcc, and etc) * bowel obstruction or impending bowel obstruction * uncontrolled severe illness, unsuitable to chemoradiotherapy (within 6 months, myocardial infarct, unstable angina, heart failure, uncontrolled arrhythmia, uncontrolled epilepsy, central nervous system disease, psychological disorder, and etc) * subject pregnant or breast feeding, or incapable of appropriate contraception * unresected synchronous colorectal cancer * history of prior pelvic radiotherapy * history of prior chemotherapy for colorectal cancer * great surgery within 4 week before study enrollment * participant in other trial within 4 week before study enrollment

Keywords: short course radiotherapy modified folfox6 delayed surgery rectal cancer synchronous metastasis liver metastasis lung metastasis
burden of illness in atrial fibrillation

Conditions: Atrial Fibrillation

Summary: the overall goal of this retrospective registry study is to investigate the burden-of.illness in atrial fibrillation (af) in denmark. several danish registries will be utilized to collect information on the diseases epidemiology including incidence and prevalence of af and stroke as well as a stroke risk stratification of the danish af-population, the clinical and economical burden (in terms of direct and indirect cost) of af and stroke to danish patients, healthcare providers / healthcare system and society as well as describing treatment patterns with anticoagulant agents and their consequences in terms of stroke, bleeds, death and according cost in a real-life setting.


Eligibility criteria:
inclusion criteria: * primary and secondary diagnosis with af; * the base population of af patients will be identified in the national patient registry. for a given period of time (2000-2013, both years inclusive) all patients with a hospital contact (admission, outpatient visit or er visit) and for whom af was the primary or secondary diagnosis code (icd10-code: di480, di481, di482, di483, di484, di489) will be included. exclusion criteria: * patients younger than 18 and older than 90 years of age.

Keywords: non-valvular atrial fibrillation
pilot study to improve therapeutic outcomes for dysphagia after radiation therapy

Conditions: Dysphagia; Oral Pharyngeal Cancer

Summary: patients with head and neck cancer treated with chemoradiation, often develop a treatment associated dysphagia. the common complaint is foods sticking in the pharynx. this study seeks to test the iowa oral performance instrument (iopi) in the management of treatment induced dysphagia following chemoradiation for oral, pharyngeal, laryngeal, hypopharyngeal cancer. this pilot study seeks to compare standard exercise therapy plus iopi to standard exercise alone to determine if recovery is enhanced and to determine if rate of recovery is accelerated.


Eligibility criteria:
inclusion criteria: * diagnosed with oral, oropharyngeal, hypopharyngeal or laryngeal cancer having non-surgical treatment with chemoradiation, or radiation therapy alone, resulting in treatment associated dysphagia. exclusion criteria: * unable to adhere to assigned therapy program due to cognitive deficits * surgical treatment for head and neck cancer * unable to give informed consent

Keywords: dysphagia oral pharyngeal cancer iowa oral performance instrument (iopi) iopi
new transporting solution in parathyroid allotransplantation

Conditions: Parathyroid Allotransplantation

Summary: the aim of this study is to measure of the parathyroid cell viability and the the amount of calcium sensing receptor of the parathyroid cells which were placed into a new transportation solution (bavu solution) for parathyroid allotransplantation.

the cold ischemia of organs, has harmful effects on the tissues due to oxidative stress and inflammation. this is physiopathologically defined as ischaemia/re-perfusion injury (iri) in organ transplantation. parathyroid allotransplantation has an increased popularity at the last decade. but the cold ischemia due to transportation of the transplant tissue is a very important problem. calcium sensing receptor plays a crucial role in regulating parathormone secretion which means controlling of the calcium-dependent systemic ion homeostasis. the investigators developed a new tissue transporting solution for parathyroid allotransplantation and the investigators measured the parathyroid cell viability and the the amount of calcium sensing receptor of the parathyroid cells at the 0., 6., 12. and 24. hours of the parathyroid cells which were placed into our new solution.

Eligibility criteria:
inclusion criteria: * patients who have parathyroid hyperplasia due to chronic renal failure exclusion criteria: * patients who refused to join to the study * patients younger than 18 years and older than 80 years. * patients who have hepatitis b, * patients who have hepatitis c, * patients who have human immunodeficiency virus (hiv)

Keywords: calcium sensing receptor parathyroid cell viability parathyroid allotransplantation transporting solution
feasibility of prediabetes remission in adults with coronary heart disease

Conditions: Prediabetic State; Coronary Heart Disease; Healthy Lifestyle; Remission

Summary: to evaluate the feasibility of a 6-month multidisciplinary program to reverse prediabetes in adults with coronary heart disease using the mediterranean diet, intermittent fasting and exercise.

the proposed study will assess the feasibility of an intensive lifestyle program to reverse newly onset prediabetes (hba1c ≥ 5.7% to 6.4%) in patients with coronary heart disease that would otherwise start a standard cardiac rehabilitation programme (12 weeks with twice weekly exercise, nutrition, and nursing counselling). the patients will be offered an upgraded 6-month intensive team-based multidisciplinary stepwise program with the goal of remitting prediabetes. the program will consist of a 3-month synchronous nutritional, exercise, and motivational intervention and of a 3-month maintenance and follow-up period. the diabepic prevent 1 study is a single-arm, open-label study aiming to demonstrate the feasibility of an intensive multidisciplinary stepwise intervention in newly diagnosed prediabetic and coronary heart disease patients, ultimately aiming to remit prediabetes. the purpose of this first study is to devise and iteratively improve participant recruitment and adherence strategies for a possible future randomized controlled trial. it also includes as goals: to study the efficacy and adherence of an intensive multicomponent lifestyle intervention, to study the proportion of patients that improve or remit their insulin resistant state, to study the changes in a variety of anthropomorphic, physical, analytic, vascular and test parameters and to better characterize the factors associated with prediabetes remission.

Eligibility criteria:
inclusion criteria: * coronary heart disease patients referred from the montreal heart institute. * aged ≥ 40 years. * recently diagnosed prediabetes (hba1c ≥ 5.7% to 6.4%) in the last 6 months. * referred to centre epic because of stable angina, acute coronary syndrome (with or without st elevation), after coronary revascularization (primary or elective) or bypass surgery. * able to perform a maximal exercise test and exercise training program in accordance with current cardiovascular rehabilitation recommendations. * able to use a smartphone application or to complete an adherence/compliance diary. * able to read, understand and sign the information and consent form. exclusion criteria: * absolute and relative contraindication to exercise testing and/or physical training. * diabetic patients (hba1c ≥ 6.5%) or patients with a hba1c value of ≥ 5.7% to 6.4% but with the help of oral hypoglycemic agents. * taking psychotropic medications that may induce mass gain (tricyclic antidepressants, mirtazapine, paroxetine, lithium, valproate, clozapine, olanzapine) or other medications known to promote mass gain (cortisone). * taking recently introduced weight-loss medications (semaglutide). * unintentional mass loss of more than 10 kg in the past year. * pregnant or nursing women.
why do people with low back pain fear and avoid lifting?

Conditions: Low Back Pain

Summary: the investigators' main focus of this trial will be to investigate * why people with low back pain perceive lifting (with a bent back) as harmful. * whether general measures of pain-related fear are associated with task-specific measures of perceived harmfulness * why people with low back pain avoid lifting (with a bent back) this will be investigated using self-report (i.e., questionnaires)


Eligibility criteria:
inclusion criteria: * low back pain \>3 months exclusion criteria: * healthy persons * low back pain \<3 months
sentinel node mapping with indocyanine green in colon cancer: a feasibility trial and a descriptive serie.

Conditions: Colon Cancer; Lymphatic Metastasis

Summary: this study is a clinical feasibility trial that will contribute to the clarification of whether sentinel node mapping with indocyanine green (icg) provides a better basis for staging of colorectal cancer.

the patients assigned for colon cancer will be operated as planned using laparoscopic techniques and the operation follows the normal procedure, in addition a sentinel node mapping is performed. indocyanine green is injected around the tumor by laparoscopic technique, the fluorescence is controlled and after 20 minutes the surgeon looks for sentinel nodes in a standardized manner. in the meantime, the surgeon proceeds with the operation as usual, except that the mesocolon can be resected only after sentinel node mapping has been performed. after surgery the surgeon and the pathologist inspect the resected colon together and agree on d1, d2 and d3 margins. any marked sentinel node(s) is verified and the location is checked on the colon diagram on the case report form. in addition, an ex vivo sentinel node mapping will be performed by the pathologist right after the surgery has ended. this is done to investigate if it is the same lymph nodes there will be identified by ex vivo as by intraoperative (in vivo) sentinel node mapping. the lymph nodes in the resected colon and mesocolon are all analysed. sentinel nodes and an equal number of randomly chosen non-sentinel nodes will be analysed further with additional sections and immune histochemistry.

Eligibility criteria:
inclusion criteria: * male and female patients above 18 years of age scheduled for laparoscopic colon cancer surgery in the department of surgery, herlev hospital or roskilde hospital. exclusion criteria: * iodine allergy * poor kidney function (as it imply an increased risk of allergic reaction), estimated glomerular filtration rate should be above 40 ml/min. * liver cirrhosis, child-pugh-score b and c \[14\] * pregnancy and lactation * previous anaphylactic reaction to a dye injection * previous abdominal surgery

Keywords: sentinel node mapping lymphatic mapping lymphatic metastasis aberrant lymphatic drainage indocyanine green icg near infrared colon cancer laparoscopic surgery
enzastaurin for breast cancer patients who previously received an anthracycline and a taxane chemotherapy

Conditions: Breast Neoplasms

Summary: the purpose of this study is to determine the effectiveness of enzastaurin in the treatment of patients with metastatic breast cancer.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of metastatic breast cancer or recurrent breast cancer where surgery can not be done for curative intent * have received prior therapy with an anthracycline (class of drugs) and a taxane (class of drugs). * tumors must not be positive for her2, but if positive, the treatment plan should not include further treatment with the drug herceptin. * disease that can be definitely measured on cat scans or other radiological tests. * may have received high dose chemotherapy for autologous stem cell support greater than or equal to 6 months of starting this study. exclusion criteria: * more than 2 chemotherapy regimens for metastatic or locally recurrent disease. * have brain cancer from breast cancer * pregnant or breastfeeding * have an inability to swallow tablets * within 6 months have had a serious heart condition

Keywords: breast cancer cancer of the breast
daily chlorhexidine bathing and infection rates in critically-ill patients

Conditions: Healthcare Associated Infections

Summary: healthcare-associated infections are a major cause of morbidity among critically ill patients. bathing critically ill patients with cloths impregnated with the broad-spectrum antimicrobial agent chlorhexidine-gluconate may decrease healthcare-associated infections. the purpose of this study is to evaluate the effect of daily bathing with disposable chlorhexidine-impregnated bathing cloths, as compared to daily bathing with disposable standard non-chlorhexidine-impregnated bathing cloths, on the rates of healthcare-associated infections in critically-ill patients. hypothesis: daily bathing of the skin with chlorhexidine-impregnated bathing cloths will result in reduced rates of healthcare-associated infections in patients admitted to intensive care units (icu).


Eligibility criteria:
inclusion criteria: * all patients admitted to the medical, surgical, trauma, cardiovascular and neuro adult intensive care units at vanderbilt university medical center exclusion criteria: 1. being cared for in the burn icu or patients with ten/sjs or burns being cared for in one of the non-burn intensive care units. 2. patients with known allergy to chlorhexidine gluconate 3. age \< 18 years old 4. patients where daily bathing would not be safe
prognostic value of respiratory system compliance under vv-ecmo on 180-day mortality in covid-19 ards.

Conditions: Ards; Mechanical Ventilation Pressure High; Extracorporeal Membrane Oxygenation

Summary: mortality of patients with covid-19 associated acute respiratory distress syndrome (cards) treated with veno-venous extra-corporal membrane oxygenation (vv-ecmo) is increasing over time since the beginning of the covid-19 pandemic. the objectives were to retrospectively describe over the first ten days after vv-ecmo implantation, the ventilatory management of cards and to assess the impact of static respiratory system compliance (crs) on the first day of vv-ecmo on 180-day mortality.


Eligibility criteria:
inclusion criteria: * patients with ards secondary to covid-19 pneumonia requiring ecmo-vv support, hospitalized in the intensive care units of the chru of nancy, marseille or bordeaux between 01/03/2020 and 31/12/2021. * age \> 18 years old exclusion criteria: * respiratory parameters not available on ten first day of vv ecmo implantation. * patient refusal to participate in the study